pharma · Refractory Focal Onset Epilepsy · Early Parkinson’s Disease
Biohaven Bioscience Ireland
Biohaven Bioscience Ireland Limited
Biohaven Bioscience Ireland is a pharma organization headquartered in GB. Primary therapeutic focus areas include Refractory Focal Onset Epilepsy, Early Parkinson’s Disease, Graves Disease, Pain, Idiopathic Generalized E
GB HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- GB
- Programs
- 7
- Drugs
- 8
- Patents
- 0
BHV7000-302
Phase 2 · small molecule · Refractory Focal Onset Epilepsy
BHV7000-302 for Refractory Focal Onset Epilepsy is a Phase 2 program (small_molecule) at Biohaven Bioscience Ireland Limited with 1 ClinicalTrials.gov record(s).
Internal code BHV7000-302
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Biohaven Bioscience Ireland Limited
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Refractory Focal Onset Epilepsy
- Status
- active
- Trials
- 1